NEW YORK, NY / ACCESSWIRE / July 21, 2021 / Labaton Sucharow, a nationally ranked and award-winning shareholder rights firm, is investigating potential securities violations and breach of fiduciary duty claims against Ardelyx, Inc. (NASDAQ:ARDX).
On July 19, 2021, the Company announced that 'it received a letter from the U.S. Food and Drug Administration (the 'FDA') on July 13, 2021, stating that, as part of its ongoing review of the Company's New Drug Application ('NDA') for the control of serum phosphorus in adult patients with chronic kidney disease ('CKD') on dialysis, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time.' The Company further announced that it requested a meeting to discuss the deficiencies identified by the FDA and was notified that the request was denied. The price of Ardelyx stock fell during after-hours trading following the announcement.
If you currently own stock or options in Ardelyx, Inc. and want to receive additional information and protect your investments free of charge, please contact David J. Schwartz using the toll-free number (800) 321-0476 or via email at email@example.com.
About the Firm
Labaton Sucharow LLP is one of the world's leading complex litigation firms representing clients in securities, antitrust, corporate governance and shareholder rights, and consumer cybersecurity and data privacy litigation. Labaton Sucharow has been recognized for its excellence by the courts and peers, and it is consistently ranked in leading industry publications. Offices are located in New York, NY, Wilmington, DE, and Washington, D.C. More information about Labaton Sucharow is available at Labaton.com.
David J. Schwartz
SOURCE: Labaton Sucharow LLP
View source version on accesswire.com: